A recent study highlights the potential of cryopreserved human placenta-derived mesenchymal stem cells (hP-MSCs) in managing knee osteoarthritis (KOA). Conducted over a year, the research demonstrates that patients receiving stem cell treatments alongside standard therapy experience significant pain reduction and improved joint function.
Study Overview
The investigation involved 26 individuals diagnosed with stage II-III KOA. Participants were divided into two groups: one received traditional hyaluronic acid (HA) injections, while the other received HA combined with three intra-articular injections of hP-MSCs administered at four-week intervals. The primary assessment tools included the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Visual Analogue Scale (VAS), MRI scans, and cytokine level measurements over six and twelve months.
Key Findings
Results indicate that the group treated with hP-MSCs alongside HA reported notable improvements in both WOMAC and VAS scores compared to the control group. These enhancements were sustained throughout the one-year follow-up period. Additionally, MRI evaluations did not show meaningful differences in cartilage thickness or optical density between the groups, suggesting that the symptomatic relief was not necessarily accompanied by structural joint changes.
• Stem cell therapy significantly reduced pain levels in KOA patients.
• Improvement persisted for at least a year post-treatment.
• hP-MSCs demonstrated an anti-inflammatory effect by lowering IL-2 levels.
• No adverse effects were linked to the stem cell injections.
• Structural joint integrity remained unchanged despite symptom relief.
The decrease in interleukin-2 (IL-2) levels among participants receiving hP-MSCs underscores the anti-inflammatory properties of the treatment. However, other cytokine levels remained unaffected, indicating a targeted immune response modulation.
Stem cell therapy offers a promising adjunct to conventional treatments for KOA, particularly for patients seeking long-term pain management without significant side effects. The absence of adverse events in the study reinforces the safety profile of hP-MSCs, making them a viable option for further exploration in osteoarthritis care. Future research should focus on larger, randomized trials to validate these findings and explore the mechanisms behind the observed clinical improvements.
Advancements in regenerative medicine, such as the use of hP-MSCs, could revolutionize the approach to treating degenerative joint diseases. By addressing inflammation and reducing pain, stem cell therapies may enhance the quality of life for millions suffering from osteoarthritis worldwide.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
